1.Name of the medicinal product

Primaquine Phosphate Tablets IP 7.5mg Taj Pharma
Primaquine Phosphate Tablets IP 15mg Taj Pharma

2.Qualitative and quantitative composition

a) Each film-coated tablet contains:
Primaquine Phosphate equivalent to Primaquine 7.5mg

Colors: Ferric Oxide Red & Titanium Dioxide 

b) Each film-coated tablet contains:
Primaquine Phosphate equivalent to Primaquine 15mg

Colors: Ferric Oxide Red & Titanium Dioxide

3.Pharmaceutical form

Oral tablet

4.Description

Primaquine Phosphate Tablets are fixed-dose combination (FDC) tablets containing, indicated for the treatment Plasmodium vivax, Plasmodium ovale and against the primary exo-erythrocytic stages of Plasmodium falciparum..

PHARMACOLOGY

Primaquine is an 8-aminoquinoline anti-protozoal agent which is highly active against exo-erythrocytic stages of Plasmodium vivax, Plasmodium ovale and against the primary exo-erythrocytic stages of Plasmodium falciparum.

Primaquine is also highly active against gametocytes of Plasmodia, especially Plasmodium falciparum.

Primaquine is readily absorbed from the gastro-intestinal tract and extensively distributed into body tissues.

Peak plasma concentration occurs about 1 to 3 hours after a dose is taken and then rapidly diminishes with a reported elimination half-life of 3 to 6 hours.

Primaquine is rapidly metabolized in the liver, its principal metabolite being carboxyprimaquine. Little unchanged drug is excreted in the urine.

INDICATIONS

PRIMAQUINE is indicated for the radical cure (prevention of relapse) of vivax and ovale malaria.

CONTRAINDICATIONS

PRIMAQUINE is contraindicated:

  • In patients who are hypersensitive to primaquine or to any ingredient in the formulation or components of the container. For a complete listing of the excipients, see AVAILABILITY section.
  • In acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus.
  • In patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow.
  • Quinacrine appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine; therefore, the use of quinacrine in patients receiving primaquine is contraindicated. Similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.
  • In patients with severe glucose-6 phosphate dehydrogenase (G6PD) deficiency
  • In pregnant women

WARNINGS

General

Discontinue the use of PRIMAQUINE promptly if signs suggestive of hemolytic anemia occur (such as darkening of the urine or a sudden decrease in hemoglobin concentration or erythrocyte count), or if there is a sudden decrease in leukocyte count.

Some adverse reactions (e.g. dizziness) may impair the patient’s ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).

Use in special groups

Observe particular caution in individuals with a personal or family history of favism, hemolytic anemia, or nicotinamide adenine dinucleotide (NADH) methemoglobin reductase deficiency.

Hemolytic anemia and G6PD deficiency:

Due to the risk of hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD) deficient patients, G6PD testing has to be performed before using primaquine. In case of severe anemia, the G6PD testing should be postponed until recovery of anemia, in order to avoid false diagnosis due to reticulocytosis.

Baseline hematocrit and hemoglobin must be checked before treatment and close hematological monitoring (e.g. at day 3 and 8) is required. Due to the limitations of G6PD tests, physicians need to be aware of residual risk of hemolysis. Adequate medical support and follow-up to manage haemolytic risk should be available.

In case of mild to moderate G6PD deficiency, a decision to prescribe primaquine must be based on an assessment of the risks and benefits of using primaquine; if primaquine administration is considered, the dosage regimen should be adapted accordingly (see DOSAGE) and close hematological monitoring is required.

Pregnancy

The safety of primaquine in human pregnancy has not been established. The use of primaquine is contraindicated during pregnancy (even if a pregnant woman is G6PD normal, the fetus may not be).

Preclinical data show a potential risk of genotoxicity and a potential embryo-fetal developmental toxicity. Although no clinical consequences have been identified, human data are limited. Patients must be informed of the potential genotoxic risk. Patients have to avoid pregnancy during treatment and for the following period after end of treatment:

− in treated women of childbearing potential, until completion of on-going ovulatory cycle (i.e. up to next menses),

− in treated males whose partners may become pregnant, for 3 months.

Lactation

It is not known whether primaquine is excreted in breast milk.

Because of the potential of primaquine to produce serious adverse reactions in nursing infants, a decision should be made whether to interrupt breast-feeding or to delay the PRIMAQUINE treatment until end of breastfeeding.

Drug Interactions

Caution is advised if primaquine is used concomitantly with other drugs that prolong the QT interval.

PRECAUTIONS

Anemia, methemoglobinemia and leukopenia have been observed following administration of large doses of primaquine; therefore, the adult dosage of 1 tablet daily for 14 days should not be exceeded. It is also advisable to make routine blood examinations, particularly blood cell counts and hemoglobin determinations, during therapy.

Due to potential for QT prolongation, caution is advised in patients with cardiac disease, a history of ventricular dysrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia (<50 bpm), and during concomitant administration with QT interval prolonging agents (see WARNINGS, ADVERSE REACTIONS, OVERDOSE).

ADVERSE REACTIONS

Cardio-vascular: Cardiac arrhythmia and QT prolongation, mainly with high dose (see also OVERDOSE).

Gastrointestinal: Nausea, vomiting, epigastric distress, and abdominal pain.

Hematologic: Leukopenia, hemolytic anemia especially in G-6-PD deficient individuals and methemoglobinemia especially in NADH methemoglobin reductase deficient individuals.

Nervous system disorders: Dizziness.

Skin and subcutaneous tissue disorders: Rash maculo-papular, pruritus.

OVERDOSE

Symptoms

Abdominal cramps, vomiting, jaundice, burning epigastric distress, CNS and cardiovascular disturbances, including cardiac arrhythmia and QT prolongation, cyanosis, methemoglobinemia, moderate leukocytosis or leukopenia, and anemia. The most striking changes are granulocytopenia and acute hemolytic anemia in G6PD deficient patients. Acute hemolysis often occurs, but complete recovery can be expected if primaquine is discontinued.

Treatment

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Management should include appropriate attempts to recover primaquine from the stomach by emesis or gastric lavage and provision of respiratory and cardiovascular support.

Sodium lactate i.v. may be used to counter the depressant effects of primaquine on the heart. Electrical pacing of the heart may be needed.

Ammonium chloride in doses up to 12 g daily orally may be given to enhance urinary excretion.

Symptomatic methemoglobinemia should be treated with 1 to 2 mg per kg of methylene blue.

DOSAGE

Primaquine is recommended only for the radical cure of vivax and ovale malaria (the prevention of relapse in vivax and ovale malaria), or following the termination of chloroquine phosphate suppressive therapy in an area where vivax or ovale malaria are endemic.

Patients suffering from an attack of vivax or ovale malaria or having parasitized red blood cells should initially receive a course of a blood schizontocide, which quickly destroys the erythrocytic parasites and terminates the paroxysm. Primaquine phosphate should then be administered in order to eradicate the exo-erythrocytic parasites.

When primaquine is indicated for the prevention of delayed primary attacks and relapse of Plasmodium vivax or Plasmodium ovale malaria in individuals who have returned home from areas where these plasmodial species are endemic, primaquine is generally initiated during the last 2 weeks of, or immediately following, therapy with chloroquine or another suitable antimalarial agent.

The G6PD status of patients should be used to guide administration of primaquine for preventing relapse. Adults:1 tablet (15 mg primaquine base) daily for 14 days.
In case of mild to moderate Glucose-6-phosphate dehydrogenase (G6PD) deficiency: 0.75 mg/kg of primaquine base once a week for 8 weeks (see WARNINGS).
Children:0.39 mg primaquine base/ kg daily for 14 days
In case of mild to moderate Glucose-6-phosphate dehydrogenase (G6PD) deficiency: 0.75 mg/kg of primaquine base once a week for 8 weeks (see WARNINGS).

 

NOTE: For radical cure of some strains of Plasmodium vivax, higher doses or longer courses may be required to overcome resistance.

Taking primaquine after a meal may reduce abdominal pain or cramps associated with ingestion of the drug.

AVAILABILITY

Each pink, film-coated, convex round tablet imprinted in black ink with a stylized W and P97 on one side and plain on the other side contains: primaquine phosphate USP 26.3 mg (equivalent to primaquine base 15 mg).

Non-medicinal ingredients: carnauba wax, cellulose (microcrystalline), lactose, magnesium stearate, Opacode Black ink S-1-177003 (contains shellac glaze; propylene glycol; N-butyl alcohol; black iron oxide; ethanol and methanol), Opadry white YS-1-7443 (contains hypromellose; polyethylene glycol 400; titanium dioxide; and polysorbate 80), polyethylene glycol 400, red iron oxide, starch and talc. Gluten and tartrazine-free.

Bottles of 100.

10 STORAGE AND STABILITY

Store between 15-30°C.

Keep away from the reach and sight of children.

Manufactured in India by:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com

Chloroquine phosphate Tablets USP 250mg Taj Pharma

Package leaflet: Information for the patient

a) Taj Pharma Chloroquine phosphate 250 mg Tablets USP.
b) Taj Pharma Chloroquine phosphate 500 mg Tablets USP.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
– Keep this leaflet. You may need to read it again.
 – If you have any further questions, ask your doctor or pharmacist.
– This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
– If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

What is in this leaflet

1. What Taj Pharma Chloroquine phosphate is and what it is used for
2. Before you are given Taj Pharma Chloroquine phosphate
3. How you will be given Taj Pharma Chloroquine phosphate
4. Possible side effects
5. How Taj Pharma Chloroquine phosphate is stored
6. Further Information

  1. What Taj Pharma Chloroquine phosphate is and what it is used for
    Taj Pharma Chloroquine phosphate Tablets contains a medicine called Taj Pharma Chloroquine phosphate. This belongs to a group of medicines called ‘anti-malarials’.

‘Anti-malarials’ can be taken in certain parts of the world to help prevent malaria. This is a serious disease spread by infected mosquitoes. Taj Pharma Chloroquine phosphate will give some degree of protection (prophylaxis) against malaria in certain countries.

Medicines to help prevent malaria (malaria prophylaxis) are recommended for:

  • People travelling to countries where malaria occurs.
  • People living in malaria areas who are not immune to malaria.

These people have little or no immunity to malaria, so they are at risk of severe attacks.

You must get medical advice on which anti-malarial medicines to take. You must ask your doctor or pharmacist if Taj Pharma Chloroquine phosphate is suitable for the part of the world that you are visiting. In some countries you may have to take Taj Pharma Chloroquine phosphate with another medicine for maximum protection.

Avoiding mosquito bites

When you are taking this medicine to prevent malaria, you should also reduce the chances of being bitten by mosquitoes.

  • Wear light-coloured, long-sleeved clothing and long trousers when you are outside after sunset.
  • Use insect repellent creams or sprays on parts of your body not covered by clothing.
  • Sleep in a properly screened room or under a mosquito net.
  • Spray to kill any mosquitoes that may have entered rooms in spite of screening.

Signs of malaria

No medicine can be guaranteed to protect against malaria in every case. If you have a high temperature (fever) during your visit to a malaria area, or up to a year after returning home, you should suspect malaria. Contact a doctor straight away and let him or her know that you have visited a malaria area.

  1. Before you are given Taj Pharma Chloroquine phosphate
    Do not take Taj Pharma Chloroquine phosphate if:
  • You are allergic to Taj Pharma Chloroquine phosphate or any of the other ingredients of Taj Pharma Chloroquine phosphate (see Section 6: Contents of the pack and other information).
  • You are taking a medicine called amiodarone (used to control the heart rate). Taj Pharma Chloroquine phosphate may increase the risk of uneven heart beats (cardiac arrhythmias) when it is taken at the same time as amiodarone. Check with your doctor or pharmacist if you are not sure.

Warnings and precautions

Check with your doctor or pharmacist before taking your medicine if:

  • You have ever had epilepsy, convulsions or fits.
  • You have ever had problems with your liver or kidneys.
  • You have ever been told that you have a rare disease of the blood pigment called ‘porphyria’ or anyone in your family has it. This is because Taj Pharma Chloroquine phosphate may cause severe symptoms of porphyria, particularly if you drink alcohol.
  • You have a scaly condition of the skin called psoriasis.
  • You have a muscle problem called ‘myasthenia gravis’. Taj Pharma Chloroquine phosphate can increase the symptoms of this condition. It can also reduce the effect of medicines used to treat this condition (neostigmine and pyridostigmine).
  • You have a blood problem called ‘glucose-6-phosphate dehydrogenase deficiency’. Taj Pharma Chloroquine phosphate may damage blood cells in people with this blood condition.

Chloroquine can cause lowering of the blood glucose level. Please ask your doctor to inform you of signs and symptoms of low blood glucose levels. A check of the blood glucose level may be necessary.

Chloroquine may cause heart rhythm disorders in some patients: caution should be taken when using chloroquine, if you were born with or have family history of prolonged QT interval, if you have acquired QT prolongation (seen on ECG, electrical recording of the heart), if you have heart disorders or have a history of heart attack (myocardial infarction), if you have salt imbalance in the blood (especially low level of potassium or magnesium, see section “Other medicines and Taj Pharma Chloroquine phosphate”).

If you experience palpitations or irregular heart beat during the period of treatment, you should inform your doctor immediately. The risk of heart problems may increase with increase of the dose. Therefore, the recommended dosage should be followed.

If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Taj Pharma Chloroquine phosphate.

If you go into hospital, tell the medical staff that you are taking Taj Pharma Chloroquine phosphate.

If you live in a country where malaria occurs, you may already be slightly immune to the disease. You must ask a doctor or pharmacist for advice before you take anti-malarial medicines.

Other medicines and Taj Pharma Chloroquine phosphate

Please tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes medicines that you buy without a prescription and herbal medicines.

Amiodarone (used to control heart rate) must not be taken at the same time as Taj Pharma Chloroquine phosphate (see section 2: what you need to know before you take Taj Pharma Chloroquine phosphate).

Tell your doctor or pharmacist if you are taking any of the following medicines. This is because Taj Pharma Chloroquine phosphate may affect the amount of these medicines in your blood.

  • Praziquantel (used to treat infections of the bowel and bladder caused by parasites).
  • Ciclosporin (mainly used by transplant patients but also used to treat rheumatoid arthritis and psoriasis).
  • Anti-convulsant medicines (used to prevent convulsions or fits).
  • Digoxin (used to treat heart problems).

Also tell your doctor or pharmacist if you are taking any of the following medicines:

  • Medicines known to affect the rhythm of your heart. This includes medicines used for abnormal heart rhythm (antiarrhythmics), for depression (tricyclic antidepressants) for psychiatric disorders (antipsychotics), for bacterial infections or against malaria (e.g. halofantrine).
  • Mefloquine (taken to prevent malaria) may increase the risk of convulsions or fits when taken at the same time as Taj Pharma Chloroquine phosphate.
  • Medicines used to treat epilepsy, as Taj Pharma Chloroquine phosphate may reduce their effectiveness.
  • Agalsidase (used to treat Fabry Disease), as Taj Pharma Chloroquine phosphate may reduce its activity.
  • Cimetidine (used to treat stomach problems). This medicine affects how Taj Pharma Chloroquine phosphate is broken down by your body and may affect the amount of Taj Pharma Chloroquine phosphate in your blood.
  • Levothyroxine (thyroid medicine).
  • Medicines like kaolin (used for diarrhoea) which are called ‘adsorbents’.
  • Antacid medicines (aluminium, calcium and magnesium salts that are used to treat heartburn or indigestion).

Adsorbents and antacid medicines may reduce the amount of Taj Pharma Chloroquine phosphate absorbed from your gut. This may mean that the full dose of Taj Pharma Chloroquine phosphate is not absorbed into your body and it will not work properly. Therefore, you should take these medicines at least four hours before or after taking your Taj Pharma Chloroquine phosphate dose.

Some medicines (for example, ciprofloxacin, cimetidine, omeprazole, pyrimethamine) may increase the amount of Taj Pharma Chloroquine phosphate in your body and this can cause side effects. It is important that you do not take any additional medicines (either prescribed or non-prescribed) before speaking to your doctor.

If you need a vaccination against rabies, make sure you have it before you start your anti-malarial medicine. If you have your rabies injection at the same time as taking your anti-malarial medicine, your rabies vaccine might not work so well.

Pregnancy

If you are pregnant or may become pregnant, talk to a doctor or pharmacist:

  • before you take Taj Pharma Chloroquine phosphate,
  • before you take any medicine to prevent malaria,
  • and before you go to a country where there is malaria.

Breast-feeding

  • If you are breast-feeding, talk to a doctor or pharmacist before taking Taj Pharma Chloroquine phosphate.
  • Although Taj Pharma Chloroquine phosphate passes into the breast milk, the amount is not enough to protect your baby from malaria. Therefore, your baby will still need to be given anti-malarial medicines. Ask your doctor or pharmacist who will be able to give you advice.

Driving and using machines

Sometimes Taj Pharma Chloroquine phosphate causes blurred eyesight or makes it difficult to focus your eyes. If this happens to you, do not drive or use any tools or machines.

  1. How you will be given Taj Pharma Chloroquine phosphate
    Always take Taj Pharma Chloroquine phosphate exactly as described in this leaflet or as your doctor or pharmacist has told you. You should check with your doctor or pharmacist if you are not sure.

When to start taking your medicine

  • Start taking this medicine one week before you enter the malaria area.
  • You must continue to take it during your stay.
  • You must keep taking this medicine for 4 weeks after leaving the malaria area.

Adults and children over 14 years

  • Take two Taj Pharma Chloroquine phosphate tablets once a week on the same day each week.

Elderly people

  • If you are an elderly person your doctor may suggest that you have blood tests. Your doctor may also decide to give you a different dose.

Children

Do not give Taj Pharma Chloroquine phosphate to children under 1 year of age. For children over 1 year of age, the dose depends on the child’s age.

  • Ages 1 to 4 years:Take half an Taj Pharma Chloroquine phosphate tablet once a week (on the same day each week).
  • Ages 5 to 8 years:Take one Taj Pharma Chloroquine phosphate tablet once a week (on the same day each week).
  • Ages 9 to 14 years:Take one and a half Taj Pharma Chloroquine phosphate tablets once a week (on the same day each week).

How to take your tablets

  • Take the tablet(s) after food.
  • Swallow the tablet(s), or part tablets, whole with a drink of water.

If you take more Taj Pharma Chloroquine phosphate tablets than you should

If you accidentally take more Taj Pharma Chloroquine phosphate tablets than you should, tell a doctor straight away. The following effects may happen: heart problems – leading to uneven heart beats.

If you forget to take your Taj Pharma Chloroquine phosphate tablets

  • If you forget to take a dose of Taj Pharma Chloroquine phosphate, take it as soon as you remember.
  • Then wait for 7 days before you take the next dose of Taj Pharma Chloroquine phosphate.
  • Carry on taking your Taj Pharma Chloroquine phosphate tablets each week, on this new day of the week.

Stopping Taj Pharma Chloroquine phosphate

Only stop taking Taj Pharma Chloroquine phosphate four weeks after leaving the malaria area or if your doctor tells you to.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

  1. Possible Side Effects
    Like all medicines, Taj Pharma Chloroquine phosphate can cause side effects, although not everybody gets them.

Serious side effects

If you experience any of the following side effects, stop taking Taj Pharma Chloroquine phosphate and get medical help or contact your doctor straight away.

  • Allergic reactions including difficulty breathing, swelling of the face, lips, tongue or throat which may cause difficulty in swallowing and an itchy rash (similar to nettle rash or hives)
  • A severe rash with blisters or peeling of the skin and possibly blisters in the mouth and nose.
  • Seeing, feeling or hearing things that are not there (hallucinations) (rare).
  • Cardiac muscle disease (cardiomyopathy) which may be fatal in case of high-dose long-term use. See section 2, warnings and precautions (rare).
  • Abnormal heart rhythm, life-threatening irregular heart rhythm (seen on ECG). See section 2, Warnings and precautions (frequency not known).
  • Liver problems which may cause yellowing of your skin or the whites of your eyes.
    If you are taking Taj Pharma Chloroquine phosphate for a long time, your doctor may suggest that you have blood tests to check how well your liver is working (rare).
  • Inflammation of the lungs causing a condition known as diffuse parenchymal lung disease.
    If you develop serious breathlessness or worsening of breathlessness seek prompt medical advice.
  • Convulsions or fits.
  • Some or complete loss of eyesight.
  • Changes to the retina of your eye (retinopathy) or to the cornea. This can lead to ‘patchy’ eyesight.
  • A rash caused by the medicine associated with an increase in the number of white blood cells (that may show up in blood tests) and symptoms involving the whole body. You may notice some or all of the following symptoms: a skin rash and fever, swelling of the face, tender generalized swollen or enlarged lymph nodes, or other symptoms suggesting involvement of other body organs including the liver, kidney or lung (such as yellowing of the skin or eyes, urinary problems, breathlessness).
  • A reduced number of blood cells. This can make you bruise more easily, get serious infections, have sudden bleeding or feel very tired or breathless. If you are taking Taj Pharma Chloroquine phosphate for a long time, your doctor may suggest that you have blood tests.

Other possible side effects (frequency not known)

When Taj Pharma Chloroquine phosphate is used to prevent or suppress malaria, these are generally not serious. If Taj Pharma Chloroquine phosphate is used for a long time, they can be more serious.

Heart

  • Changes in the way your heart works (known as ‘electrocardiographic changes’).
  • Low blood pressure. This may make you feel faint or dizzy.

Nervous system

  • Feeling dizzy or light-headed.
  • Involuntary muscle movements or spasms.

Behaviour

  • Mood changes or other effects on behaviour. These include feeling depressed, confused or anxious.

Skin

  • Skin rash, including a scaly rash (psoriasis) or itch.
  • Peeling skin.
  • Discolouration of the skin or mucous membranes (such as the inside of your mouth).
  • Being sensitive to sun light which may require medical treatment.
  • The appearance of small fluid filled bumps on the skin.

Hair

  • Changes in hair colour.
  • Hair loss.

Eyes

  • Blurred eyesight.
  • Problems with your colour vision.
  • Difficulty in focussing your eyes.
  • Double vision.

If you are taking Taj Pharma Chloroquine phosphate for a long time, your doctor may suggest that you have eye tests.

Ears

  • Hearing loss.
  • Ringing in the ears (tinnitus).

Stomach and gut

  • Stomach upsets, feeling sick (nausea), being sick (vomiting), diarrhoea or stomach cramps.

Other

  • Weakening of your muscles (neuromyopathy and myopathy).
  • Lowering of the blood glucose level.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

  1. How Taj Pharma Chloroquine phosphate is stored
    Keep this medicine out of the sight and reach of children. Your medicine could harm them.
    Do not store your medicine above 30°C.
    Protect the tablets from light and moisture.
    Keep the tablets in the container they came in.
    Do not take Taj Pharma Chloroquine phosphate after the expiry date stated on the carton. The expiry date refers to the last day of that month.
    Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer required. This will help to protect the environment.
  2. Further information

What Taj Pharma Chloroquine phosphate contains
The active substance in Taj Pharma Chloroquine phosphate Tablets is Chloroquine phosphate.
A)  Each tablet contains 250mg of Taj Pharma Chloroquine phosphate (equivalent to 155 mg of chloroquine base).
B)  Each tablet contains 500mg of Taj Pharma Chloroquine phosphate (equivalent to 155 mg of chloroquine base).

The other ingredients are magnesium stearate and maize starch.

 What Taj Pharma Chloroquine phosphate looks like and contents of the pack
Taj Pharma Chloroquine phosphate Tablets are white and round.
Taj Pharma Chloroquine phosphate Tablets come in packs of 20, 30, 50, 60, 100 tablets.
Not all pack sizes may be marketed.

Manufactured in India by:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com